🎉 M&A multiples are live!
Check it out!

Replimune Group Valuation Multiples

Discover revenue and EBITDA valuation multiples for Replimune Group and similar public comparables like Pharming, Galapagos, and Vivoryon Therapeutics.

Replimune Group Overview

About Replimune Group

Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3.


Founded

2017

HQ

United States of America
Employees

331

Website

replimune.com

Financials

LTM Revenue $3.3M

LTM EBITDA -$263M

EV

$118M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Replimune Group Financials

Replimune Group has a last 12-month revenue of $3.3M and a last 12-month EBITDA of -$263M.

In the most recent fiscal year, Replimune Group achieved revenue of n/a and an EBITDA of -$206M.

Replimune Group expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Replimune Group valuation multiples based on analyst estimates

Replimune Group P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue n/a n/a XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$167M -$206M XXX XXX XXX
EBITDA Margin -Infinity% -Infinity% XXX XXX XXX
Net Profit -$118M -$174M XXX XXX XXX
Net Margin -Infinity% -Infinity% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Replimune Group Stock Performance

As of April 15, 2025, Replimune Group's stock price is $8.

Replimune Group has current market cap of $578M, and EV of $118M.

See Replimune Group trading valuation data

Replimune Group Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$118M $578M XXX XXX XXX XXX $-2.86

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Replimune Group Valuation Multiples

As of April 15, 2025, Replimune Group has market cap of $578M and EV of $118M.

Replimune Group's trades at 36.1x LTM EV/Revenue multiple, and -0.4x LTM EBITDA.

Analysts estimate Replimune Group's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Replimune Group and 10K+ public comps

Replimune Group Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $118M XXX XXX XXX
EV/Revenue n/a XXX XXX XXX
EV/EBITDA -0.5x XXX XXX XXX
P/E -2.5x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -0.6x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Replimune Group Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Replimune Group Valuation Multiples

Replimune Group's NTM/LTM revenue growth is 1244%

Replimune Group's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $0.7M for the same period.

Over next 12 months, Replimune Group's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Replimune Group's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Replimune Group and other 10K+ public comps

Replimune Group Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth n/a XXX XXX XXX XXX
EBITDA Margin n/a XXX XXX XXX XXX
EBITDA Growth 23% XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee n/a XXX XXX XXX XXX
Opex per Employee $0.7M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue n/a XXX XXX XXX XXX
Opex to Revenue n/a XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Replimune Group Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics and Vaccines & Immunotherapies comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Replimune Group M&A and Investment Activity

Replimune Group acquired  XXX companies to date.

Last acquisition by Replimune Group was  XXXXXXXX, XXXXX XXXXX XXXXXX . Replimune Group acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Replimune Group

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Replimune Group

When was Replimune Group founded? Replimune Group was founded in 2017.
Where is Replimune Group headquartered? Replimune Group is headquartered in United States of America.
How many employees does Replimune Group have? As of today, Replimune Group has 331 employees.
Who is the CEO of Replimune Group? Replimune Group's CEO is Dr. Sushil Patel, PhD.
Is Replimune Group publicy listed? Yes, Replimune Group is a public company listed on NAS.
What is the stock symbol of Replimune Group? Replimune Group trades under REPL ticker.
When did Replimune Group go public? Replimune Group went public in 2018.
Who are competitors of Replimune Group? Similar companies to Replimune Group include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Replimune Group? Replimune Group's current market cap is $578M
What is the current revenue of Replimune Group? Replimune Group's last 12-month revenue is $3.3M.
What is the current EBITDA of Replimune Group? Replimune Group's last 12-month EBITDA is -$263M.
What is the current EV/Revenue multiple of Replimune Group? Current revenue multiple of Replimune Group is 36.1x.
What is the current EV/EBITDA multiple of Replimune Group? Current EBITDA multiple of Replimune Group is -0.4x.
Is Replimune Group profitable? Yes, Replimune Group is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.